Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131154 · ClinicalTrials.gov registry record · Phase 3
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
A Phase 3 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
NCT03131154 is a Phase 3 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 123 participants.
The verdict
NCT03131154, a Phase 3 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
Study Summary
A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.
Interventions
- DRUG ADX-102 Ophthalmic Solution (0.5%)
- DRUG Vehicle of ADX-102 Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2017-04-26 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03131154
The ClinicalTrials.gov registry entry for NCT03131154 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADX-102 Ophthalmic Solution (0.5%) is the first listed.
NCT03131154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03131154 about?
NCT03131154 is a clinical study titled "SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.". A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.
What is the current status of trial NCT03131154?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2017-04-26. Estimated completion is 2019-04-26.
What interventions are being tested in trial NCT03131154?
The interventions under investigation include: ADX-102 Ophthalmic Solution (0.5%) (DRUG), Vehicle of ADX-102 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT03131154?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.